Indeed, our limited study of RPL22L1 protein levels and outcomes in CRC revealed that in our small cohort, patients with CRC expressing high levels of RPL22L1 exhibit a significant reduction in survival. The gene discussed is RPL22L1; the disease is colorectal carcinoma.